|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Department of Chemical and Screening Sciences, Wyeth Research, Cambridge, Massachusetts 02140, USA
2 Women's Health and Musculoskeletal Biology, Wyeth Research, Cambridge, Massachusetts 02140, USA
3 Department of Biological Technologies, Wyeth Research, Cambridge, Massachusetts 02140, USA
(RECEIVED October 10, 2007; FINAL REVISION October 15, 2007; ACCEPTED October 16, 2007)
Aggrecanases are now believed to be the principal proteinases responsible for aggrecan degradation in osteoarthritis. Given their potential as a drug target, we solved crystal structures of the two most active human aggrecanase isoforms, ADAMTS4 and ADAMTS5, each in complex with bound inhibitor and one wherein the enzyme is in apo form. These structures show that the unliganded and inhibitor-bound enzymes exhibit two essentially different catalytic-site configurations: an autoinhibited, nonbinding, closed form and an open, binding form. On this basis, we propose that mature aggrecanases exist as an ensemble of at least two isomers, only one of which is proteolytically active.
Keywords: protein structure; enzymes; metalloproteins; aggrecanases
This article has been cited by other articles:
![]() |
W. Gao, P. J. Anderson, and J. E. Sadler Extensive contacts between ADAMTS13 exosites and von Willebrand factor domain A2 contribute to substrate specificity Blood, September 1, 2008; 112(5): 1713 - 1719. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |